Prokidney Corp

Prokidney Corp has a negative net income of $68.99 million and a negative total equity of $1.01 billion, indicating significant financial distress. The company's liquidity position is weak, with a current ratio of 9.13, but its cash and equivalents of $108.54 million provide some short-term flexibility. The company's profitability is severely challenged, with a return on equity of 6.82% and a negative return on assets of -20.56%. These metrics fall well below the industry norms for a healthcare diagnostics firm, suggesting operational inefficiencies and poor asset utilization. Geographically and segment-wise, Prokidney's revenue concentration is not disclosed in the available data. However, the lack of segment-specific financials implies a potential overreliance on a single product line or market, which could increase business risk. The company's growth trajectory is negative, with a net income decline of $68.99 million and an operating income loss of $165.01 million. Analysts have not provided specific revenue growth projections, but the current financial performance suggests a challenging outlook for the near term. Risk factors include a high liquidity risk due to negative equity and a negative net income. The company has a low dilution risk, with no immediate filing-based dilution flags detected. However, the negative equity position may necessitate future equity raises, which could dilute existing shareholders. Recent events include a significant drop in net income and operating income, as well as a negative free cash flow of $160.23 million. These financial results have likely influenced the analyst price targets, which range from $1.00 to $12.00, with a mean of $6.50 and a median of $7.00.